The Bristol-Myers Squibb (E.R. Squibb & Sons, LLC) U.S. Distribution Center in Mt. Vernon, Indiana, has received accreditation by the National Association of Boards of Pharmacy (NABP®) as a verified-accredited wholesale distributor (VAWD®) for prescription drugs.

Bristol-Myers Squibb was recognized as 8th among 500 of America’s largest corporations in Newsweek’s 2009 Green Ranking.

For the 12th consecutive year, Bristol-Myers Squibb was included among Working Mother Magazine’s 100 Best Companies.

Our corporate website was recognized with the Best in Class award for a pharmaceutical company in 2009 by the Interactive Media Awards.

Bristol-Myers Squibb was recently recognized in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.

Bristol-Myers Squibb's Investor Relations department was rated the best in the pharmaceutical business by investors polled by Institutional Investor magazine, a leading international business-to-business publisher focused primarily on international finance.

Bristol-Myers Squibb awarded the Allicense 2009 Breakthrough Alliance Award for collaboration with Exelixis. This is the second year in a row that the company has been presented with this prestigious recognition, which honors the world's best and most innovative partnerships between biotechnology and pharmaceutical companies.

FORTUNE China named Bristol-Myers Squibb China a Top Ten Green Company for 2009 in recognition of Bristol-Myers Squibb's hepatitis awareness, prevention and care efforts in Asia. Since 2002, Bristol-Myers Squibb China has partnered with the Bristol-Myers Squibb Foundation and local non-profit organizations on 11 hepatitis prevention and control projects that have directly benefited seven million people.

The National Association for Female Executives selected Bristol-Myers Squibb as a Top 50 Company for Executive Women in 2009. This marks the seventh straight year the company earned this honor. To make the list, companies must have at least two women on the board and track gender in executive-level jobs, including the percentage of women who are direct reports to CEOs, running major divisions or managing country operations.

The Corporate Responsibility Officer CRO Magazine ranked Bristol-Myers Squibb number one on its annual 100 Best Corporate Citizens list. CRO looked at the largest publicly traded companies in the U.S. to determine the top leaders in seven categories: environment, climate change, human rights, philanthropy, employee relations, finance and governance.

Barron’s 2009 Most Respected Companies Survey includes Bristol-Myers Squibb as the world’s 40th most respected company. The survey reflects opinions of money managers for the 100 largest public companies in the world based on stock market capitalization. A variety of attributes contribute to the overall score, including strong management, sound business strategy, ethical practices and financial performance.

Calvert, a leader in socially responsible investing, has created the Calvert Social Index®, a broad-based, rigorously constructed benchmark for measuring the performance of socially responsible companies. Calvert’s Social Research Department analyzes the top 1,000 largest U.S. companies annually. Bristol-Myers Squibb has been on its Social Index of companies since 2003.

DiversityBusiness.com has named Bristol-Myers Squibb as a Top 50 Organization for Multicultural Business Opportunities for 2009, which marks the ninth year in a row that the company has earned this distinction. Known as The Div50, the ranking has become the most recognized and respected ranking of companies that differentiate themselves in the marketplace through their relationships with diverse businesses.

The Asian American Legal Defense and Education Fund honored Sandra Leung, senior vice president, general counsel and corporate secretary, as a recipient of its 2009 Justice in Action Award. The award, which recognizes exceptional individuals for their outstanding achievements and contributions in advancing justice and equality, was presented in March in New York.

The Division of Medicinal Chemistry of the American Chemical Society will present John E. Macor, executive director, Neuroscience Discovery Chemistry, Research and Development, with the 2009 Robert M. Scarborough Memorial Award. This prestigious achievement recognizes scientists under the age of 50 who have documented success in the discovery of pharmaceutical compounds and who have made significant research contributions in medicinal chemistry. Macor was cited for the discovery of an anti-migraine medicine as well as a number of other clinical discoveries. The society will bestow the award at its annual meeting later this year.

Bristol-Myers Squibb achieved a perfect score (100 percent) in the 2009 Corporate Equality Index for its treatment of gay, lesbian, bisexual and transgender employees, consumers and investors. The Human Rights Campaign Foundation's Corporate Equality Index report, released each fall, provides an in-depth analysis and rating of large U.S. employers and their policies and practices pertinent to gay, lesbian, bisexual and transgender employees, consumers and investors. This year’s index rated 583 businesses on a scale from 0 to 100 percent.

Bristol-Myers Squibb is profiled as one of “50 Green, Profitable Companies” in Green Biz, published by American Benchmark Press in 2008. “Saving Lives and Spotted Owls” is the title of the Bristol-Myers Squibb chapter, which highlights the company’s sponsorship of local endangered species in the countries and states where it operates. The illustrated, art-quality book was compiled with the help of Ceres, a leading coalition of investors and environmental leaders in Boston.

Bristol-Myers Squibb’s alliance with Adnexus Therapeutics for the discovery and development of adnectin-based cancer therapeutics, and its subsequent acquisition, received the Allicense 2008 Breakthrough Alliance Award. The annual award, dubbed the “Deal of the Year,” is presented by Recombinant Capital (Recap), a San-Francisco-based subscription data base and advisory services firm. The Bristol-Myers Squibb/Adnexus alliance – one of five candidates for this year’s award – won based on votes cast by business development and licensing executives from the pharmaceutical and biotech industries.

Bristol-Myers Squibb ranked third among America’s Most Generous Corporations by donating 1.4 percent of operating income or $59 million in 2007, according to a 2008 survey by Forbes Magazine.

On behalf of Bristol-Myers Squibb, Elliott Sigal, executive vice president, chief scientific officer and president, Research and Development, accepted the 2008 Corporate Leadership in Lupus Award from the Board of Directors of the Lupus Foundation of America at their Fifth Annual Awards Gala in Washington, D.C. Celebrating advances in Lupus research and education, the gala attracts more than 650 attendees including members of Congress, federal agency leaders, business professionals, medical and health organization representatives, researchers, clinicians, and lupus patients and their families.

Storebrand analysts added Bristol-Myers Squibb to its "best in class" status index in 2007 for leading environmental and social performance. Bristol-Myers Squibb’s shares therefore qualify for inclusion in Storebrand's socially responsible investment funds. A financial services company based in Norway, Storebrand is engaged in three major areas: investments, life insurance, and banking, and has €25 billion in assets under management. It monitors and analyzes the environmental and social performance of more than 2,600 companies.

Bristol-Myers Squibb’s Building 115 in New Brunswick, New Jersey received the 2008 Facility of the Year Award for Equipment Innovation. The award is sponsored by the International Society for Pharmaceutical Engineering, INTERPHEX and Pharmaceutical Processing magazine. Bristol-Myers Squibb was cited for bringing early and late phase clinical development and manufacturing together within a single facility to create a Pharmaceutical Development Center of Excellence.

Marci Hanlon, director, Consumer Marketing, ORENCIA® (abatacept) was named one of the Top 25 Direct-to-Consumer [DTC] Pharmaceutical Marketers of the Year in 2008, by DTC Perspectives, the leading publication for consumer marketers in the pharmaceutical industry. The seventh annual Top 25 list consists of marketers from pharmaceutical, biotech and device manufacturers. This year’s Top 25 were selected after an industry-wide nomination and screening process.